Scilex Holding Company SCLX Scilex Pharma — Royalty Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Scilex Holding Company in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Scilex Holding Company's scilex pharma — royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Scilex Holding Company's scilex pharma — royalty expense?
- Scilex Holding Company (SCLX) reported scilex pharma — royalty expense of $1.2M in Q1 2026.
- How has Scilex Holding Company's scilex pharma — royalty expense changed year-over-year?
- Scilex Holding Company's scilex pharma — royalty expense increased by 33.3% year-over-year, from $900K to $1.2M.
- What is the long-term trend for Scilex Holding Company's scilex pharma — royalty expense?
- Over 3 years (2022 to 2025), Scilex Holding Company's scilex pharma — royalty expense has grown at a 37.7% compound annual growth rate (CAGR), from $2.3M to $6M.
- What does scilex pharma — royalty expense mean?
- This metric represents the periodic payments made by the pharmaceutical segment to third-party licensors or patent holders for the right to use intellectual property, technology, or trademarks. It reflects the cost structure associated with commercializing licensed products and is a key indicator of the segment's reliance on external innovation versus proprietary development. Monitoring this expense helps investors assess the impact of licensing agreements on the segment's overall gross margins and long-term profitability.